
| 2012 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| 2008 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
Total number of projects: 3
As coordinator: 0
As participant: 3
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2013 | 0 | 11.959.743 | 2.244.340 | 2 | ||
| 2012 | 0 | 5.512.424 | 551.242 | 1 | ||
Total number of partners: 21
Partner loyalty:
Frequent Partner: (> 2 projects): 3
Rare Partner: 18
Frequent / Rare Partner Ratio: 0.17
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2013-10-01 | BIOIMAGE-Neuromuscular Diseases | BIOIMAGE-NMD | participant | 5.960.533 | 9 |
| 2013-06-01 | Consortium for Products across Europe in Duchenne Muscular Dystrophy | SCOPE-DMD | participant | 5.999.210 | 5 |
| 2012-11-01 | A phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53 | SKIP-NMD | participant | 5.512.424 | 10 |